caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever" and the new york times has noted that "the pace of new discoveries and applications is dizzying." caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub
Company profile
Ticker
CRBU
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Antler Holdco, LLC • Arboreal Holdco, LLC • Biloba Holdco, LLC • Microbe Holdco, LLC ...
IRS number
453728228
CRBU stock data
Latest filings (excl ownership)
8-K
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4 Apr 24
S-8
Registration of securities for employees
11 Mar 24
10-K
2023 FY
Annual report
11 Mar 24
8-K
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
11 Mar 24
8-K
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8 Jan 24
8-K
Departure of Directors or Certain Officers
22 Dec 23
8-K
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
12 Dec 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 104.10 mm | 104.10 mm | 104.10 mm | 104.10 mm | 104.10 mm | 104.10 mm |
Cash burn (monthly) | (no burn) | (no burn) | 4.88 mm | 9.10 mm | 9.60 mm | 8.08 mm |
Cash used (since last report) | n/a | n/a | 32.57 mm | 60.77 mm | 64.08 mm | 53.96 mm |
Cash remaining | n/a | n/a | 71.53 mm | 43.34 mm | 40.02 mm | 50.15 mm |
Runway (months of cash) | n/a | n/a | 14.7 | 4.8 | 4.2 | 6.2 |
Institutional ownership, Q3 2023
90.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 129 |
Opened positions | 30 |
Closed positions | 24 |
Increased positions | 57 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 336.97 bn |
Total shares | 81.38 mm |
Total puts | 74.20 k |
Total calls | 93.80 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Partner Fund Management | 6.72 mm | $32.14 bn |
BLK Blackrock | 6.08 mm | $29.08 bn |
Avidity Partners Management | 6.05 mm | $28.92 bn |
STT State Street | 5.35 mm | $25.59 bn |
PFE Pfizer | 4.69 mm | $19.93 mm |
Vanguard | 3.82 mm | $18.27 bn |
Deerfield Management | 3.50 mm | $16.73 bn |
Point72 Asset Management | 3.50 mm | $16.73 bn |
Rachel E. Haurwitz | 3.35 mm | $37.21 mm |
Paradigm Biocapital Advisors | 2.94 mm | $14.07 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
20 Feb 24 | Jason O'Byrne | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 59,224 |
20 Feb 24 | Jason O'Byrne | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
20 Feb 24 | Barbara G Mcclung | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 409,566 |
20 Feb 24 | Barbara G Mcclung | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
20 Feb 24 | Ruhi Ahmad Khan | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 33,000 |
20 Feb 24 | Ruhi Ahmad Khan | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
20 Feb 24 | Rachel E. Haurwitz | Common Stock | Grant | Acquire A | No | No | 0 | 118,700 | 0.00 | 158,700 |
20 Feb 24 | Rachel E. Haurwitz | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 546,950 | 3.72 mm | 546,950 |
20 Feb 24 | Steven Kanner | Common Stock | Grant | Acquire A | No | No | 0 | 33,000 | 0.00 | 387,037 |
20 Feb 24 | Steven Kanner | Option to purchase Common Stock Common Stock | Grant | Acquire A | No | No | 6.81 | 153,000 | 1.04 mm | 153,000 |
News
Caribou Biosciences Announces Oral Presentation On In Vivo Cas12a chRDNA Genome Editing At The 27th Annual Meeting Of ASGCT
15 Apr 24
Kura Sushi Posts Upbeat Sales, Joins Caribou Biosciences, Krispy Kreme And Other Big Stocks Moving Higher In Friday's Pre-Market Session
5 Apr 24
Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
4 Apr 24
HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Raises Price Target to $24
19 Mar 24
Investor Sentiment Improves Following Inflation Data, Dow Jumps Over 200 Points
13 Mar 24
Press releases
Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
15 Apr 24
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
4 Apr 24
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
27 Mar 24